EUROAPI SA engages in manufacturing and supply of active pharmaceutical ingredient solutions for healthcare companies. The company is headquartered in Paris, Ile-De-France and currently employs 3,428 full-time employees. The company went IPO on 2022-05-06. The firm is engaged in the development, manufacture and supply of active-ingredient solutions to its healthcare partners. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates (morphine, codeine, thebaine, etc. ), analgesics, etc. The firm also provides technologies and develops molecules through it’s Contract Development and Manufacturing Organization (CDMO). It’s CDMO services include Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones and Opiates & Controlled Substances. The company has production sites located in France, the United Kingdom, Germany, Italy and Hungary.
Follow-Up Questions
EAPIF 주식의 가격 성능은 어떻습니까?
EAPIF의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Euroapi SA의 주요 사업 주제나 업종은 무엇입니까?
Euroapi SA은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
Euroapi SA의 시가총액은 얼마입니까?
Euroapi SA의 현재 시가총액은 $0입니다
Euroapi SA는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 8명의 분석가가 Euroapi SA에 대한 분석 평가를 실시했으며, 이는 0명의 강력한 매수, 1명의 매수, 4명의 보유, 6명의 매도, 그리고 0명의 강력한 매도를 포함합니다
